Bristol Myers Squibb believes the drug Cobenfy, which comes from a clinical trial in the 1990s, can treat psychosis associated with Alzheimer's disease[3]. The company plans to expand this drug, acquired for $14 billion through the acquisition of Karuna Therapeutics, to other neuropsychiatric indications, including Alzheimer's psychosis[1][2]. In the pivotal phase 3 study ADEPT-2, they found discrepancies at several sites, so after consultation with the FDA and an interim analysis by an independent group, they decided to recruit more patients to reach the original goal[1][5][7]. The results of the study are expected sometime in 2026 instead of the end of 2025[5]. The company is conducting three pivotal studies of Cobenfa for psychosis in Alzheimer's disease, two of which must be positive for FDA approval[5]. Cobenfy has already received approval for the treatment of schizophrenia in adults and achieved sales of $27 million in the first quarter of 2025[2]. Analysts estimate potential peak sales of $2.6 billion for the Alzheimer's psychosis indication alone[5].